IP Library Granted Patent US 12,016,945
Granted Patent B2
US 12,016,945 · App. 17/334,057 · Granted Jun 25, 2024

Cosmetic composition containing, as active ingredient, albumin, hyaluronic acid or collagen in cell culture medium

Inventors: Chan Wha Kim (Seoul, KR); Young Joon Kim (Tenafly, NJ)
Assignee: BIOCOZ GLOBAL PTE. LTD.
A61K8/65A61K8/19A61K8/36A61K8/64A61K8/673A61K8/675A61K8/735A61K38/385A61K38/39A61K47/02A61K47/12A61K47/22A61K47/26A61P17/00A61P27/02A61Q19/005A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,016,945
App. No.
17/334,057
Granted
Jun 25, 2024
Kind
B2
Abstract

A composition contains a cell culture medium and, as an active ingredient, albumin, hyaluronic acid or collagen. The composition is useful as a cosmetic or pharmaceutical purpose for alleviating, preventing or treating skin wounds, skin diseases or skin conditions, by enhancing recovery capability of cells. The cell culture medium may be a serum-free medium.

Claims (24)

1. A composition comprising:

a cell culture medium comprising an amino acid component, a vitamin component, an inorganic salt component, and sodium pyruvate; and

any one selected from the group consisting of albumin, hyaluronic acid, and collagen,

wherein the amino acid component comprises 1 part by weight of serine, 0.2 to 1.2 parts by weight of glycine, 0.08 to 0.3 part by weight of L-alanine, 2 to 7 parts by weight of L-arginine hydrochloride, 0.2 to 0.9 part by weight of L-cysteine hydrochloride-monohydrate, 10 to 18 parts by weight of L-glutamine, 0.8 to 2.0 parts by weight of L-histidine hydrochloride-monohydrate, 1.0 to 5.0 parts by weight of L-lysine hydrochloride, 0.2 to 1.2 parts by weight of L-methionine, 0.2 to 1.2 parts by weight of L-proline, 1.0 to 5.0 parts by weight of L-threonine, and 1.0 to 5.0 parts by weight of L-valine, each based on the 1 part by weight of serine.

2. The composition of claim 1 , wherein the cell culture medium is an animal cell culture medium.

3. The composition of claim 1 , wherein

the vitamin component is at least one vitamin selected from the group consisting of i-inositol, thiamine hydrochloride, niacinamide and pyridoxine hydrochloride, or a combination thereof, and

wherein the inorganic salt component is an inorganic salt selected from the group consisting of sodium chloride (NaCl), sodium hydrogen carbonate (NaHCO 3 ), potassium chloride (KCl), calcium chloride (CaCl 2 )) and sodium hydrogen phosphate monohydrate (NaH 2 PO 4 —H 2 O), or a combination thereof.

4. The composition of claim 1 , wherein the cell culture medium is composed of glycine, L-alanine, L-arginine hydrochloride, L-cysteine hydrochloride-monohydrate, L-glutamine, L-histidine hydrochloride-monohydrate, L-lysine hydrochloride, L-methionine, L-proline, L-serine, L-threonine, L-valine, i-inositol, thiamine hydrochloride, niacinamide, pyridoxine hydrochloride, sodium chloride (NaCl), sodium hydrogen carbonate (NaHCO 3 ), potassium chloride (KCl), calcium chloride (CaCl 2 )) (anhydrous), sodium hydrogen phosphate monohydrate (NaH 2 PO 4 —H 2 O), and sodium pyruvate.

5. The composition of claim 3 , wherein the vitamin component comprises 0.2 to 0.9 part by weight of i-inositol, 0.04 to 0.8 part by weight of thiamine hydrochloride, 0.04 to 0.8 part by weight of niacinamide and 0.04 to 0.8 part by weight of pyridoxine hydrochloride, based on 1 part by weight of amino acid serine.

6. The composition of claim 3 , wherein the inorganic salt component comprises 50 to 200 parts by weight of sodium chloride (NaCl), 50 to 120 parts by weight of sodium hydrogen carbonate (NaHCO 3 ), 2.0 to 20 parts by weight of potassium chloride (KCl), 1.0 to 10 parts by weight of calcium chloride (CaCl 2 )) (anhydrous) and 0.5 to 5.0 parts by weight of sodium hydrogen phosphate monohydrate (NaH 2 PO 4 —H 2 O), based on 1 part by weight of amino acid serine.

7. The composition of claim 1 , wherein the cell culture medium comprises 0.5 to 5.0 parts by weight of sodium pyruvate, based on 1 part by weight of amino acid serine.

8. The composition of claim 1 , wherein the cell culture medium is a serum-free medium.

9. The composition of claim 2 , wherein the animal cell culture medium is selected from the group consisting of DMEM/F-12 (Dulbecco's Modified Eagle's Medium/Nutrient Mixture F-12), DMEM, MEMα (Minimum Essential Mediumα), BME (Basal Medium Eagle), GMEM (Glasgow Minimum Essential Medium), RPMI-1640 Medium, and a combination thereof.

10. The composition of claim 1 , wherein the albumin is human serum albumin or bovine serum albumin.

11. The composition of claim 1 , wherein the albumin is comprised at a concentration of 10 to 1000 μg/ml.

12. The composition of claim 1 , wherein the hyaluronic acid is comprised at a concentration of 0.01 to 1 mg/ml.

13. The composition of claim 1 , wherein the collagen is collagen I or collagen III.

14. The composition of claim 13 , wherein the collagen I is comprised at a concentration of 1 to 100 μg/ml.

15. The composition of claim 13 , wherein the collagen III is comprised at a concentration of 2 to 200 μg/ml.

16. A cosmetic composition for improving skin condition comprising the composition of claim 1 as an active ingredient.

17. The cosmetic composition of claim 16 , wherein the skin condition improvement is selected from the group consisting of decreasing development of wrinkles, decreasing-skin aging, improvement of skin elasticity, skin regeneration, injury or wound healing, corneal regeneration, skin irritation alleviation, and a combination thereof.

18. A pharmaceutical composition for treating a skin disorder comprising the composition of claim 1 as an active ingredient.

19. The pharmaceutical composition of claim 18 , wherein the skin disorder is selected from the group consisting of atopic dermatitis, allergy, skin eczema, acne, psoriasis, pruritus, and a combination thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2026
From: BIOCOZ GLOBAL PTE. LTD.
To: BG PHARMACEUTICAL, INC.
Reel/Frame 075422/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2022
From: BIOCOZ GLOBAL KOREA CORP.
To: BIOCOZ GLOBAL PTE. LTD.
Reel/Frame 062187/0225 →
Continuity (3)
Division 16089510
Provisional Application 62316948 · Apr 1, 2016
Related Publication 20210353519A1 · Nov 18, 2021